Unbiased metabolome screen links serum urate to risk of Alzheimer's disease

Neurobiol Aging. 2022 Dec:120:167-176. doi: 10.1016/j.neurobiolaging.2022.09.004. Epub 2022 Sep 15.

Abstract

Alzheimer's disease (AD) is a progressive and fatal neurodegenerative disease caused by a combination of genetic and environmental risk factors. The serum metabolome refers to a set of small-molecules which are an important determinant of cellular health. We obtained genome-wide association study (GWAS) summary statistics for serum concentrations of 376 metabolites which were population matched with 2 GWAS studies of AD. For each metabolite we performed 2-sample MR (2SMR) using an inverse variance weighted (IVW) estimate for significance testing. After Bonferroni multiple testing correction one metabolite was causally linked to AD in both GWAS: serum urate. This result was supported by robust 2SMR measures and sensitivity analyses. We applied 2SMR to test for a causal relationship between serum urate and other neurodegenerative diseases: Parkinson disease (PD) and Amyotrophic lateral sclerosis (ALS). In ALS but not PD we identified a nominally significant link between serum urate and disease-risk, although in this case increased serum urate was protective. We conclude that serum urate is a modulator of risk for neurodegeneration. Our work has implications for the design of preventative interventions.

Keywords: Alzheimer's Disease; Mendelian Randomization; Metabolome; Serum urate.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Alzheimer Disease* / genetics
  • Amyotrophic Lateral Sclerosis* / genetics
  • Genome-Wide Association Study
  • Humans
  • Mendelian Randomization Analysis
  • Metabolome
  • Neurodegenerative Diseases*
  • Parkinson Disease* / genetics
  • Polymorphism, Single Nucleotide
  • Uric Acid

Substances

  • Uric Acid